U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Feingold KR, Anawalt B, Blackman MR, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

Cover of Endotext

Endotext [Internet].

Show details

Guidelines for the Management of High Blood Cholesterol

, MD and , MD.

Author Information and Affiliations

Last Update: May 28, 2022.


The cholesterol hypothesis holds that high blood cholesterol is a major risk factor for atherosclerosis cardiovascular disease (ASCVD) and lowering cholesterol levels will reduce risk for ASCVD. This hypothesis is based on epidemiological evidence that both within and between populations higher cholesterol levels raise the risk for ASCVD; and conversely, randomized clinical trials (RCTs) show that lowering cholesterol levels will reduce risk. Cholesterol in the circulation is embedded in lipoproteins. The major atherogenic lipoproteins are low density lipoproteins (LDL), very low-density lipoproteins (VLDL), and remnants. Together they constitute non-high-density lipoproteins (non-HDL). Clinically these lipoproteins are identified by their cholesterol (C) content, i.e., LDL-C, VLDL-C, and non-HDL-C. Atherogenic lipoproteins can be reduced by both lifestyle intervention and cholesterol-lowering drugs. The efficacy of lifestyle intervention is best demonstrated in epidemiological studies, whereas efficacy of drugs is revealed through RCTs. Currently available cholesterol-lowering drugs are statins, ezetimibe, bempedoic acid, bile acid sequestrants, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, niacin, fibrates, and n-3 fatty acids (e.g., icosapent ethyl). The latter three generally are reserved for patients with hypertriglyceridemia; here they can be combined with statins that together lower non-HDL-C. Highest priority for cholesterol-lowering therapy goes to patients with established ASCVD (secondary prevention). RCTs in such patients show that “lower is better” for cholesterol reduction. The greatest risk reductions are attained by reducing LDL-C concentrations by at least 50% with a high intensity statin; and if necessary, to achieve LDL-C < 55-70 mg/dL, combining a statin with ezetimibe or PCSK9 inhibitor. For primary prevention, a decision to initiate statin therapy is made on multiple factors (i.e., presence of diabetes or severe hypercholesterolemia, estimated 10-year risk or lifetime risk for ASCVD, presence of risk enhancing factors (e.g., metabolic syndrome and chronic kidney disease); and if in doubt, detection of subclinical atherosclerosis (e.g., coronary artery calcium [CAC]). A reasonable goal for primary prevention using moderate-intensity statin therapy is an LDL-C in the range of 70-99 mg/dL. Both population epidemiology and genetic epidemiology show that low serum cholesterol throughout life will minimize lifetime risk of ASCVD. For this reason, cholesterol-lowering intervention, preferably through lifestyle change, should be carried out as early as possible. If cholesterol concentrations are very high in younger adults, it sometimes may be judicious to introduce a cholesterol-lowering drug. For complete coverage of all related areas of Endocrinology, please visit our on-line FREE web-text, WWW.ENDOTEXT.ORG.


Atherosclerotic cardiovascular disease (ASCVD) remains the foremost cause of death among chronic diseases. Its prevalence is increasing in many countries. This increase results from aging of the population combined with atherogenic lifestyles. Even so, mortality from ASCVD has been declining in most developed countries. This decline comes from improvements in preventive measures and better clinical interventions. One of the most important advances in the cardiovascular field resulted from identifying risk factors for ASCVD. Risk factors directly or indirectly promote atherosclerosis, or they otherwise predispose to vascular events. The major risk factors are cigarette smoking, dyslipidemia, hypertension, hyperglycemia, and advancing age. Dyslipidemia consists of elevations of atherogenic lipoproteins (LDL, VLDL, Lp(a), and remnants) and low levels of HDL. Advancing age counts as a risk factor because it reflects the impact of all risk factors over the lifespan. Several other factors, called risk enhancing factors, associate with higher risk for ASCVD (1). Lifestyle factors (for example, overnutrition and physical inactivity) contribute importantly to both major and enhancing risk factors. Hereditary factors undoubtedly contribute to the identifiable risk factors; but genetic influences also affect ASCVD risk through other ways not yet understood (2).


The first evidence for a connection between serum cholesterol levels and atherosclerosis came from laboratory animals (3). Feeding cholesterol to various animal species raises serum cholesterol and causes deposition of cholesterol in the arterial wall (3). The latter recapitulates early stages of human atherosclerosis. Subsequently, in humans, severe hereditary hypercholesterolemia was observed to cause premature atherosclerosis and ASCVD (3). Later, population surveys uncovered a positive association between serum cholesterol levels and ASCVD (4,5). Finally, clinical trials with cholesterol-lowering agents documented that lowering of serum cholesterol levels reduces the risk for ASCVD (6). These findings have convinced most investigators that the cholesterol hypothesis is proven. Moreover, the relationship between cholesterol levels and ASCVD risk is bidirectional; raising cholesterol levels increases risk, whereas reducing levels decreases risk (Figure 1).

Figure 1. . The Cholesterol Hypothesis.

Figure 1.

The Cholesterol Hypothesis. Between the years 1955 and 1985, many epidemiologic studies showed a positive relation between cholesterol levels and atherosclerotic cardiovascular disease (ASCVD) events. Over the next 30 years, a host of randomized controlled clinical trials have demonstrated that lowering cholesterol levels will reduce the risk for ASCVD. This bidirectional relationship between cholesterol levels and ASCVD provides ample support for the cholesterol hypothesis.

Epidemiological Evidence

A relationship between cholesterol levels and ASCVD risk is observed in both developing and developed countries (4,5). Populations with the lowest cholesterol levels and LDL-C levels have the lowest rates of ASCVD. Within populations, individuals with the lowest serum cholesterol or LDL-C levels carry the least risk. In other words, “the lower, the better” for cholesterol levels holds, both between populations and for individuals within populations.

Pre-Statin Clinical Trial Evidence

Another line of evidence supporting the cholesterol hypothesis comes from randomized controlled trials (RCTs) of cholesterol-lowering therapies. Several earlier RCTs tested efficacy by reducing cholesterol through diet, bile acid sequestrants, or ileal exclusion operation (Table 1) (4). When taken individually, results from some of the smaller trials were not definitive; but meta-analysis, which combines data from all RCTs, demonstrated significant risk reduction due to cholesterol lowering. In addition, before the discovery of statins, several secondary-prevention RCTs were performed with various cholesterol-lowering drugs. Although some of these trials showed significant risk reduction, others gave equivocal results. But again when taken together, meta-analysis demonstrated ASCVD risk reduction from cholesterol reduction (7).

Table 1.

Summary of Pre-Statin Clinical Trials of Cholesterol-Lowering Therapy

InterventionNo. trialsNo. treatedPerson-yearsMean cholesterol reduction (%)CHD incidence
(% change)
CHD Mortality

This table is derived from National Cholesterol Education Program Adult Treatment Panel III (4)

Statins and Clinical Trial Evidence

Statins were discovered in the 1970s by Endo of Japan (8). These drugs lower cholesterol by inhibiting cholesterol synthesis in the liver. They block HMG CoA reductase, a key enzyme in cholesterol synthesis. This inhibition enhances the liver’s synthesis of LDL receptors. The latter, discovered by Brown and Goldstein (9), remove LDL and VLDL from the bloodstream, which lowers serum cholesterol levels. Statin have proven to be highly efficacious with few side effects. The development of statins as a cholesterol-lowering drug has been actively pursued by the pharmaceutical industry. Seven statins have been approved for use in clinical practice by the FDA (for a detailed discussion of statins see (10)). Over the past three decades, a series of RCTs have been carried out that documents the efficacy and safety of statin therapy. In these RCTs, statin therapy has been shown to significantly reduce morbidity and mortality from ASCVD. Although individual RCTs produced significant results, the strongest evidence of benefit comes from meta-analysis. i.e., by combining data from all the trials (6).

Meta-analysis has shown that for every mmol/L (39 mg/dl) reduction in LDL-C with statin therapy there is an approximate 22% reduction in ASCVD events (6,11-14). Another report (15) showed that an almost identical relationship holds when several different kinds of LDL-lowering therapy were analyzed together. This response appears to be consistent throughout all levels of LDL-C. Individual statins vary in their intensity of cholesterol-lowering therapy at a given dose (1,10) (Table 2). For example, per mg per day, rosuvastatin is twice as efficacious as atorvastatin, which in turn is twice as efficacious as simvastatin. Statins are best classified according to percentage reductions in LDL-C. As shown in Table 2, moderate- intensity statins reduce LDL-C by 30-49%, whereas high-intensity statins reduce LDL-C by 50%. On average, a 35% LDL-C reduction by moderate-intensity statin reduces risk by approximately one third, whereas high-intensity statins lower risk by about one-half. But, in fact, absolute reductions vary depending on baseline levels of LDL-C. For example, for a baseline LDL-C of 200 mg/dL, a 50% reduction in LDL-C equates to a 100 mg/dL (2.6 mmol/L) decline; this translates into a 59% reduction in 10-year risk for ASCVD events. In contrast, in a patient with a baseline LDL-C a 100 mg per dL, a 50% reduction in LDL-C equates to a 50 mg/dL (1.3 mmol/L) decline, which will reduce ASCVD risk by about 30%. Thus, at lower and lower levels of LDL-C, progressive reductions of LDL-C produce diminishing benefit from cholesterol-lowering therapy. This modifies the aphorism "lower is better". Whereas the statement is true, it must be kept in mind that there are diminishing benefits from intensifying cholesterol-lowering therapy when LDL-C levels are already low. One needs to balance the benefits of further reducing LDL-C levels with the risks and costs of additional therapy.

Table 2.

Categories of Intensities of Statins

20-25% ↓ LDL-C
30-49%↓ LDL-C
High Intensity
50%↓ LDL-C
Lovastatin10-20 mg40-80 mg
Pravastatin10-20 mg40-80 mg
Simvastatin10 mg20-40 mg
Fluvastatin20-40 mg80 mg
Pitavastatin1-4 mg
Atorvastatin5 mg10-20 mg40-80 mg
Rosuvastatin5-10 mg20-40 mg

Non-Statin Cholesterol-Lowering Drugs

Beyond statins, other agents are currently available or loom on the horizon (Table 3). Bile acid sequestrants inhibit intestinal absorption of bile acids, which like statins raise hepatic LDL receptors (10). They are moderately efficacious for reducing LDL-C concentrations. A large RCT showed that bile acid sequestrants significantly reduce risk for CHD in patients with baseline elevations in LDL-C (16). Theoretically, bile acid sequestrants could enhance risk reduction in patients with ASCVD who are treated with statins.

Ezetimibe blocks cholesterol absorption in the intestine and also raises hepatic LDL receptor activity (10). It moderately lowers LDL-C (15-25%). The combination of statin + ezetimibe is additive for LDL-C lowering (17). A clinical trial (18) demonstrated that adding ezetimibe to moderate intensity statins in very high-risk patients with ASCVD is beneficial showing that combination therapy reduced risk of cardiovascular events more than a statin alone (18). In this trial, the higher the risk, the greater was risk reduction (19). Ezetimibe is a generic drug and relatively inexpensive.

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor and thereby inhibits cholesterol synthesis leading to an increase in LDL receptor activity (20). Bempedoic acid is a pro-drug and conversion to its CoA-derivative is required for activity and this occurs primarily in the liver. Bempedoic acid typically lowers LDL-C by 15-25% (10,20). The effect of bempedoic acid on cardiovascular disease is currently being evaluated in a large clinical trial.

Niacin and fibrates, which are primarily triglyceride-lowering drugs, have been used for many years. They modestly reduce cholesterol levels as well. Their effects on ASCVD risk vary. Niacin used alone appears to attenuate risk, but when used in combination with high-intensity statin, any incremental benefit is minimal (21). Like niacin, fibrates moderately reduce risk for CHD when used alone in patients with hypertriglyceridemia; risk reduction is less in those who do not have elevated triglycerides (22). When fibrates are used in combination with statins, risk for severe myopathy is greater than for statins alone. Fenofibrate is the preferred fibrate in combination with statins because it carries the lowest risk of myopathy (23). For a detailed discussion of niacin and fibrates see the Endotext chapter on Triglyceride Lowering Drugs (24).

Omega-3 fatty acids also lower serum triglyceride (24). In one notable RCT, treatment of high-risk, hypertriglyceridemic patients with statin + 2 g of the omega-3 fatty acid icosapent ethyl twice daily, compared to placebo, significantly reduced the risk of ischemic events, including cardiovascular death (25). In contrast, a recent RCT that randomized high risk hypertriglyceridemic patients on statin therapy to an omega-3 carboxylic acid formulation 4 grams per day did not observe any benefits on ASCVD (26). In both trials the reduction in triglyceride levels was similar and the explanation for the different results in these trials is uncertain. For a detailed discussion of omega-3 fatty acidssee the Endotext chapter on Triglyceride Lowering Drugs (24).

Other LDL-lowering drugs include microsomal triglyceride transfer protein (MTP) inhibitors (27) and RNA antisense drugs that block hepatic synthesis of apolipoprotein B (no longer available) (28). Both of these drugs inhibit secretion of atherogenic lipoproteins into the circulation. At present their use is restricted to patients with severe hypercholesterolemia. Evinacumab is a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3) that is approved for the treatment of homozygous familial hypercholesterolemia (29). Evinacumab decreases LDL-C levels by approximately 50% independent of LDL receptor activity by accelerating the clearance of VLDL thereby reducing the production of LDL (30). Another class of drugs inhibits cholesterol ester transfer protein (CETP); these agents lower LDL-C levels as well as raising HDL-C (31,32). RCTs show their benefit is small, if any, so the pharmaceutical industry shows little interest in further development and CETP inhibitors are not FDA approved.

Finally, a class of drugs inhibits a circulating protein called proprotein convertase subtilisin/kexin type 9 (PCSK9); the PCSK9 protein promotes degradation of LDL receptors and raises LDL-C levels (10). Inhibition of PCSK9 markedly lowers LDL-C concentrations (10,33). Recent reports indicate that PCSK9 inhibitors reduce risk in ASCVD patients at very high risk when combined with statins (34,35). PCSK9 inhibitors are useful for patients who are statin intolerant, those with very high baseline LDL-C, such as familial hypercholesterolemia, or patients at very high risk for additional ASCVD events.

For additional information on cholesterol and triglyceride lowering drugs see the chapters in Endotext that address these topics (10,24).

Table 3.

Non-Statin Cholesterol Lowering Drugs

Drug ClassMechanism of ActionEffects on Plasma LipidsLDL-C loweringSide effects
Bile acid sequestrantsImpairs reabsorption of bile acids
Raise LDL receptor activity
Reduces LDL
Raises VLDL
Minimal effect on HDL
15-25%, depending on doseConstipation
GI distress
Increases TG
EzetimibeImpairs absorption of cholesterol
Raises LDL receptor activity
Reduces LDL
Reduces VLDL
Minimal effect on HDL
Bempedoic acidInhibitor of ATP-citrate lyase leading to decreased cholesterol synthesis and an increase in LDL receptor activityReduces LDL15-25%Increases uric acid leading to gout
Tendon rupture has been reported
NiacinReduces hepatic secretion of VLDLReduces VLDL
Reduces LDL
Raises HDL
5-20%Flushing, rash, raise plasma glucose, hepatic dysfunction, others
FibratesReduces secretion of VLDL
Enhances degradation of VLDL
Reduces VLDL
(lowers TG 25-35%)
Small effect on LDL
Raises HDL
5-15%Myopathy (in combination with statins)
Uncommonly various others
MTP inhibitors
Approved for treatment of homozygous familial hypercholesterolemia
Reduces hepatic secretion of VLDLReduces VLDL and LDL50+%Fatty liver
(RNA antisense)
No longer available
Reduces hepatic secretion of VLDLReduces VLDL and LDL50+%Fatty liver
CETP inhibitors
Not approved by FDA
Blocks transfer of cholesterol from HDL to VLDL&LDLRaises HDL
Lowers LDL
PCSK9 inhibitors
Recommended for ASCVD patients at high risk
Blocks effects of PCSK9 to destroy LDL receptorsLowers LDL45-60%
Approved for treatment of homozygous familial hypercholesterolemia
Blocks angiopoietin-like protein 3 (ANGPTL3)Lowers LDL
Lowers TG (~50%)
Lowers HDL (~30%)
Approx. 50%


National Cholesterol Education Program (NCEP)

The most influential guidelines for cholesterol management in the United States have been those developed by the NECP. This program was sponsored by the National Heart, Lung and Blood Institute and included many health-related organizations in the United States (36). Between 1987 and 2004, three major Adult Treatment Panel (ATP) reports (4,37,38) and one update were published (39) (Table 4).

Table 4.

National Cholesterol Education Program’s Adult Treatment Panel (ATP) Reports

ThrustPrimary preventionSecondary preventionHigh-risk primary preventionVery high risk
DrugsBile acid resins Nicotinic acid FibratesSame as ATPI +StatinsSame as ATP IISame as ATP III
LDL-C goal
Low risk <190 Moderate risk <160 High risk < 130Low risk <160 Moderate risk <130 High risk <100Low risk <160 Moderate risk <130 Moderately high risk <130
High risk < 100
Low risk <160 Moderate risk <130
Moderately high risk <130 High risk < 100 Very high risk < 70

ATP reports identified LDL-C as the major target of cholesterol-lowering therapy. The intensity of LDL-lowering therapy was based on aggregate knowledge from multiple sources in the cholesterol field. Priority was given to the clinical trial evidence when available. ATP I (1987) emphasized lifestyle therapy for primary prevention. Use of cholesterol-lowering drugs was down-played in ATP I. ATP II (1993) placed more emphasis on secondary prevention; this was because a large meta-analysis of RCTs using cholesterol-lowering drugs confirmed CHD risk reduction. ATP III (2001) added more emphasis on high-risk primary prevention. At each successive ATP report, the intensity of LDL lowering therapy was increased with lower LDL-C goals.

The NCEP put highest priority for cholesterol management for patients with clinical forms of atherosclerotic disease. The latter included coronary heart disease, clinical carotid artery disease, peripheral arterial disease, and abdominal aortic aneurysm. ASCVD is the inclusive term for these conditions. The 10-year risk for future cardiovascular events in patients with established ASCVD is usually > 20%. In ATP III, the presence of ASCVD of any type warranted an LDL-C goal of < 100 mg/dL. For high-risk patients with hypertriglyceridemia, a non-HDL-C goal of < 130 mg/dL was recommended.

For primary prevention, ATP III identified four levels of risk for increasing intensity of LDL-C lowering. Different LDL-C goals were set for different levels of risk (Table 4). Risk for CHD was calculated using Framingham risk scoring. Framingham risk factors included cigarette smoking, hypertension, elevated total cholesterol, low HDL-C, and advancing age. A 10-year risk 20% for CHD was called high risk. Moderately high risk was defined as a 10-year risk of 10-19%; at this level of risk, cholesterol-lowering drugs were considered to be cost-effective. A 10-year risk of < 10% was divided into moderate risk and low risk depending on the presence or absence of major risk factors. Moderate risk corresponds to a 10-year risk for CHD of approximately 5-9%. Generally speaking, cholesterol-lowering drugs were not recommended for low- to- moderate risk individuals except when LDL-C levels are high.

In 2004, ATP III underwent an update and set an optional LDL-C goal of < 70 mg/dL for patients deemed to be at very high risk for future CHD events. This option included CHD plus other atherosclerotic conditions and/or multiple major risk factors. This progression of treatment intensity was made possible by the results of several clinical trials with statin therapy.

Transfer of NHLBI Guidelines to American Heart Association (AHA) and the American College of Cardiology (ACC)

In 2013, NHLBI made the decision to remove treatment guidelines from its agenda. This was done even though it had almost finished writing prevention guidelines. These included guidelines for high blood cholesterol, high blood pressure, obesity, and nutrition. Late in this process, the guideline process was transferred to the (American Heart Association) AHA and American College of Cardiology (ACC). Then in 2013 the NHLBI guidelines for high blood cholesterol were modified to fit the criteria for guideline development required by AHA/ACC. The 2013 cholesterol guidelines (40) adhered closely to the Institute of Medicine (National Academy of Medicine) recommendations for evidence-based guidelines (41). These recommendations advocated priority to randomized controlled trials (RCTs) as the foundation of evidence-based medicine. The NHLBI cholesterol committee carried out an extensive review of the literature and limited recommendations based largely to RCTs. Most acceptable RCTs had utilized statin therapy in middle-aged persons. Therefore, the 2013 report committee did not include detailed recommendations for younger or older adults. Recommendations were largely limited to the age range 40-75 years. High-intensity statin therapy was recommended for patients with established ASCVD. For primary prevention, risk was stratified by use of a pool cohort equation (PCE), which are derived from five large population studies in the United States (42). The PCE was an extension of the Framingham Heart Study risk equations. 10-year risk for ASCVD was based on the following risk factors: age, gender, cigarette smoking, blood pressure, total cholesterol, HDL cholesterol, and presence or absence of diabetes. Although the PCE was validated in another large study (43), it has been criticized by some investigators as being imprecise for many individuals or specific groups (44-48).

For primary prevention, an effort was made to determine what level 10-year risk is associated with efficacy of reduction of ASCVD from statin RCTs. It was determined that statins are effective for risk reduction when 10-year risk for ASCVD is 7.5%. Most primary prevention trials employed moderate intensity statins, so these were recommended for most patients; but in one RCT (49), a high-intensity statin appeared to produce greater risk reduction than found with moderate-intensity statins. So high-intensity statins were considered a favorable option in patients at higher 10-year risk. Notably LDL-C goals were not emphasized. It was recognized that these recommendations may not be optimal for all patients; therefore, consideration should be given to any extenuating circumstances that could modify the translation of RCTs directly into clinical care. A clinician patient risk discussion thus was advocated for all patients to consider the pros and cons of statin therapy.


2018 cholesterol guidelines were revised by AHA/ACC in collaboration with multiple other societies concerned with preventive medicine (1). These guidelines extended those published in 2013. They expanded recommendations to include children, adolescents, young adults (20-39 years), and older patients (> 75 years). Although RCTs may be lacking in these categories, epidemiology and clinical studies indicate that high blood cholesterol is an important risk factor for future ASCVD in these age ranges. From the evidence acquired over many years related to the cholesterol hypothesis, it is reasonable to craft recommendations based on the totality of the evidence. In the following, 2018 guidelines will be highlighted in relation to general areas of cholesterol management as identified by all the previous national and international guidelines. These guidelines proposed a top-10 list of recommendations to highlight the key points. These key points will be examined.

Lifestyle Intervention


There is widespread agreement in the cardiovascular field that lifestyle factors contribute to the risk for ASCVD. These factors include cigarette smoking, sedentary life habits, obesity, and an unhealthy eating pattern. The ACC/AHA strongly recommends that a healthy lifestyle be adopted throughout life. These recommendations are strongly supported by 2018 cholesterol guidelines. They are the foundation for cardiovascular prevention and should receive appropriate attention in clinical practice (50). For a detailed discussion of the effect of diet on lipid levels and atherosclerosis see the Endotext chapter The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels (51).

Secondary Prevention


The strongest evidence for efficacy of statin therapy is a meta-analysis of RTCs carried out in patients with established ASCVD. As previously mentioned, the best fit line comparing percent ASCVD versus LDL-C in secondary prevention studies demonstrates that for every mmol/L (39mg/dL) reduction in LDL-C the risk for ASCVD is decreased by approximately 22% (11). High intensity statins typically reduce LDL-C by 50% or more; this percentage reduction occurs regardless of baseline levels of LDL-C. This explains why the guidelines set a goal for LDL-C secondary prevention to be a 50% reduction in levels. There are two options to achieve such reductions. RCTs give priority to use of high-intensity statins. But second, if high-intensity statins are not tolerated, similar LDL-C lowering can be attained by combining a moderate-intensity statin with ezetimibe (18). An approach to lowering LDL-C in patients with ASCVD is shown in Figure 2.

Figure 2.

Figure 2.

Secondary Prevention in Patients with Clinical ASCVD (1)


2018 guidelines defined very high risk of future ASCVD events as a history of multiple ASCVD events or one major event plus multiple high-risk conditions (Table 5). This definition is based in large part on subgroup analysis of the IMPROVE-IT trial (18,19).

Table 5.

Very High Risk of Future ASCVD Events (1)

Major ASCVD Events
Recent ACS (within the past 12 months)
History of MI (other than recent acute coronary syndrome event listed above)
History of ischemic stroke
Symptomatic peripheral arterial disease (history of claudication with ABI <0.85, or previous revascularization or amputation)
High Risk Conditions
Age ≥65 y
Heterozygous familial hypercholesterolemia
History of prior coronary artery bypass surgery or percutaneous coronary intervention outside of the major ASCVD event(s)
Diabetes mellitus
CKD (eGFR 15-59 mL/min/1.73 m2)
Current smoking
Persistently elevated LDL-C (LDL-C ≥100 mg/dL [≥2.6 mmol/L]) despite maximally tolerated statin therapy and ezetimibe
History of congestive heart failure

ABI indicates ankle-brachial index; CKD indicates chronic kidney disease

Recent RCTs have demonstrated that addition of non-statins to statin therapy can enhance risk reduction. These RCTs (and their add-on drugs) were IMPROVE-IT (ezetimibe) (18), FOURIER (evolocumab) (34), and ODYSSEY OUTCOMES (alirocumab) (35). All RCTs were carried out in patients at very high-risk. For IMPROVE-IT, addition of ezetimibe to statin therapy produced an additional 6% reduction in ASCVD events. In this trial, baseline LDL-C on moderate-intensity statin alone averaged about 70 mg/dL; in spite of this low level, further LDL lowering with addition of ezetimibe enhanced risk reduction. RCTs with the two PCSK9 inhibitors (evolocumab and alirocumab) restricted recruitment to patients having LDL-C 70 mg/dL on maximally tolerated statin+ ezetimibe. In these RCTs, duration of therapy was only about 3 years. A marked additional LDL lowering was achieved. In both trials, risk for ASCVD events was reduced by 15%.

2018 guidelines allow consideration of PCSK9 inhibitor as an add-on drug if patients are at very high risk for future ASCVD events and have an LDL-C 70 mg/dL during treatment with maximally tolerated statin plus ezetimibe (Figure 3). This latter threshold LDL-C was chosen because it was a recruitment criteria for PCSK9 inhibitor therapy in reported RTCs (34,35)

An important question about use of PCSK9 inhibitors is whether they are cost-effective When they first became available, they were marketed at a very high cost, which was widely considered to be excessive. More recently, the cost of these drugs has declined considerably. An analysis of cost-effectiveness has shown that at current prices in very high-risk patients PCSK9 inhibitors can be cost-effective (52). Another analysis (53) of approximately 1 million patients with ASCVD in the Veterans Affairs system indicate that approximately 10% of patients will be classified as very high risk and having LDL-C 70 mg/dL while taking maximal statin therapy plus ezetimibe. These later patients are potential candidates for PCSK9 inhibitors.

Figure 3.

Figure 3.

Secondary Prevention in Patients with Very High-Risk ASCVD (1)

Primary Prevention


Patients with severe hypercholesterolemia are known to be at relatively high risk for developing ASCVD (54,55). In view of massive evidence that elevated LDL-C promotes atherosclerosis and predisposes to ASCVD, it stands to reason that such patients deserve intensive treatment with LDL-lowering drugs. RCTs with cholesterol-lowering drugs demonstrate benefit of statin therapy in patients with severe hypercholesterolemia (56,57). It is not necessary to calculate 10-year risk in such patients. Moreover, patients who have extreme elevations of LDL-C (e.g., heterozygous familial hypercholesterolemia) may be candidates for PCSK9 inhibitors if LDL-C cannot be lowered sufficiently with maximal statin therapy plus ezetimibe.


Middle-aged patients with diabetes have an elevated lifetime risk for ASCVD (58). The trajectory of risk is steeper in patients with diabetes than in those without. For this reason, estimation of 10-year risk for ASCVD with pooled cohort equation (PCE) is not a reliable indicator of lifetime risk. Meta-analysis of RCTs in middle-aged patients with diabetes treated with moderate intensity statins therapy shows significant risk reduction (14). Hence, most middle-aged patients with diabetes deserve statin therapy. It is not necessary to measure 10-year risk before initiation of statin therapy in these patients. With progression of age and accumulation of, multiple risk factors, increasing the intensity of statin therapy or adding ezetimibe seems prudent (Tables 6 and 7).

Table 6.

Diabetes Specific Risk Enhancers That Are Independent of Other Risk Factors in Diabetes (1)

Long duration (≥10 years for type 2 diabetes mellitus or ≥20 years for type 1 diabetes mellitus
Albuminuria ≥30 mcg of albumin/mg creatinine
eGFR <60 mL/min/1.73 m2
ABI <0.9

ABI indicates ankle-brachial index

Table 7.

ASCVD Risk Enhancers (1)

Family history of premature ASCVD
Persistently elevated LDL > 160mg/dl (>4.1mmol/L
Chronic kidney disease
Metabolic syndrome
History of preeclampsia
History of premature menopause
Inflammatory disease (especially rheumatoid arthritis, psoriasis, HIV)
Ethnicity (e.g., South Asian ancestry)
Persistently elevated triglycerides > 175mg/dl (>2.0mmol/L)
Hs-CRP > 2mg/L
Lp(a) > 50mg/dl or >125nmol/L
Apo B > 130mg/dl
Ankle-brachial index (ABI) < 0.9


This discussion is necessary to put a patient’s total risk status in perspective. The risk discussion should always begin with a review of the critical importance of lifestyle intervention. This is true for all age groups. Beyond the issue of lifestyle, the discussion can further consider the potential benefit of a cholesterol-lowering drug, especially statin therapy. When the latter may be beneficial, the provider should next review major risk factors and estimated 10-year risk for ASCVD derived from the pooled cohort equation (PCE) risk calculator (59) (https://www.acc.org/guidelines/hubs/blood-cholesterol). Estimation of lifetime risk is also useful, particularly in younger individuals. All major risk factors (e.g., cigarette smoking, elevated blood pressure, LDL-C, hemoglobin A1C [if indicated], should be discussed. In patients 40-75 years, the 10-year risk estimate is most useful. In these patients, four categories of 10-year risk for ASCVD are recognized: low risk (<5%); borderline risk (5-7.4%); intermediate risk (7.5-19.9%), and high risk ( 20%). Estimates of lifetime risk for patients 20-39 years also are available (https://www.acc.org/guidelines/hubs/blood-cholesterol or https://qrisk.org/lifetime/index.php). Three other components of the risk discussion are: risk enhancing factors (see #8), possible measurement of coronary artery calcium (CAC) (see #9), and a review of extenuating life circumstances (issues of cost and safety considerations, as well as patient motivation and preferences). The decision to initiate statin therapy should be shared between clinician and patient. All of these factors deserve a full discussion in view of the fact that statin therapy represents a lifetime commitment to taking a cholesterol-lowering drug.

Patients should also recognize that atherosclerosis begins early in life and progresses overtime before manifesting as clinical disease. The cumulative LDL-C levels (“LDL-C years”) strongly influence the timing of clinical manifestation (figure 4). In patients with high cholesterol levels (homozygous and heterozygous familial hypercholesterolemia) ASCVD can occur early in life whereas in patients with loss of function mutations in PCSK9 and low cholesterol level have a reduced occurrence of ASCVD.

Figure 4. . Relationship between cumulative LDL-C exposure, age, and the development of the clinical manifestations of ASCVD.

Figure 4.

Relationship between cumulative LDL-C exposure, age, and the development of the clinical manifestations of ASCVD. Figure from reference (60).

Additionally, patients should be appraised of comparisons of the reduction in ASCVD events in individuals with genetic variations resulting in life-long reductions in LDL-C levels vs. individuals treated with statins to lower LDL-C later in life. Variants in the HMG-CoA reductase, NPC1L1, PCSK9, ATP citrate lyase, and LDL receptor genes result in a lifelong decrease in LDL-C and a 10mg/dL decrease in LDL-C with any of these genetic variants was associated with a 16-18% decrease in ASCVD events (61). As noted above a 39mg/dL decrease in LDL-C in the statin trials resulted in a 22% decrease in ASCVD events. Thus, a life-long decrease in LDL-C levels results in a decrease in ASCVD events that is three to four times as great as that seen with short-term LDL-C lowering with drugs later in life suggesting that the sooner the LDL-C level is lowered the better the prevention of cardiovascular events.


A 10-year risk 7.5% does not mandate statin therapy but indicates that moderate-intensity statins can reduce risk by 30-40% with a minimum of side effects (62). This fact alone can justify moderate intensity statin therapy, but only if other considerations noted above (#6) are taken into account in the risk discussion. An approach to lipid lowering in primary prevention patients is shown in figure 5.

Figure 5.

Figure 5.

Approach to Primary Prevention in Patients without LDL-C >190mg/dl or Diabetes (1)


If risk assessment based on PCE is equivocal or ambiguous, the presence of risk enhancing factors in patients at intermediate risk (10-year risk 7.5 to 19.9%), can tip the balance in favor of statin therapy. Risk enhancing factors are shown in Table 7.


CAC measurements are a safe and inexpensive method to assess severity of coronary atherosclerosis. CAC scores generally reflect lifetime exposure to coronary risk factors and therefore in young individuals (men < 40 years of age; women < 50 years of age) the long-term predictive value is limited because the CAC score is often 0. Studies show that CAC accumulation is a strong predictor of probability of ASCVD events (63). A CAC core of zero generally is accompanied by few if any ASCVD events over the subsequent decade. A CAC score of 1-100 Agatston units is associated with relatively low rates of ASCVD, both in middle-aged and older patients. In contrast, a CAC >100 Agatston units carries a risk well into the statin-benefit zone. Data such as these led to the following recommendation of 2018 guidelines for patients at intermediate risk by PCE.


If CAC is zero, treatment with statin therapy may be withheld or delayed, except in cigarette smokers, those with diabetes mellitus, those with a strong family history of premature ASCVD, and possibly chronic inflammatory conditions such as HIV.


A CAC score of 1 to 99 Agatston units favors statin therapy in intermediate-risk patients ≥55 years of age, whereas benefit in 40-54 years is marginal (note these focuses on 10-year risk and a CAC score in this range in a younger individual is predictive of long-term risk (64)).


A CAC score ≥100 Agatston units (or ≥75th percentile), strongly favors statin therapy, unless otherwise countermanded by clinician–patient risk discussion.



Remember that the LDL-C goal for patients with ASCVD or severe hypercholesterolemia is a 50% reduction in LDL-C. For most such patients, this goal can be achieved by high-intensity statin therapy + ezetimibe. In ASCVD patients at very high risk, the goal is an LDL-C lowering >50% and LDL-C < 70 mg/dL. To achieve these goals, it may be necessary to combine a PCSK9 inhibitor with maximal statin therapy + ezetimibe. For statin therapy in primary prevention, the goal is a lowering of 35%. This goal can be achieved in most patients with a moderate intensity statin + ezetimibe

2018 guidelines did not set a precise on-treatment LDL-C target of therapy, but instead, offer percent reductions as goals of therapy. Baseline levels of LDL-C can be obtained either by chart review or withholding statin therapy for about two weeks. In addition, on-treatment LDL-C can provide useful information about efficacy of treatment (Figure 6). This figure shows expected LDL-C levels for 50% or 35% reductions at different baseline levels of LDL-C. For example, in secondary prevention, an on-treatment LDL-C of <70 mg/dL can be considered adequate treatment regardless of baseline LDL-C. On-treatment levels in the range of 70-100 mg/dL are adequate if baseline-LDL C is known to be in the range of 140- 200 mg/dL; if there is uncertainty about baseline levels, reevaluation of statin adherence and reinforcement of treatment regimen is needed. For optimal treatment, on-treatment levels in this range warrant consideration of adding ezetimibe to maximal statin therapy. If on treatment LDL-C is 100 mg/dL, the treatment regimen is probably inadequate, and intensification of therapy is needed. For primary prevention, the LDL-C goal is a reduction 35%, and a similar scheme for evaluating efficacy of therapy can be used.

Figure 6. . Predicted on-treatment LDL-C compared to baseline LDL-C and suggested actions for each category of on-treatment LDL-C in secondary and primary prevention.

Figure 6.

Predicted on-treatment LDL-C compared to baseline LDL-C and suggested actions for each category of on-treatment LDL-C in secondary and primary prevention.

Other Issues


2018 guidelines offered suggestions for management of high blood cholesterol in children, adolescents, young adults (20-39 years), and elderly patients > 75 years. There is no strong RCT evidence to underline cholesterol management in these populations. Instead, treatment suggestions depend largely on epidemiologic data. Lifestyle intervention is a primary method for cholesterol treatment in these age groups. However, under certain circumstances LDL-lowering drugs may be indicated. This is particularly the case for patients with familial hypercholesterolemia or similar forms of very high LDL-C. In young adults, particularly those with other risk factors, LDL lowering drug therapy (statin or ezetimibe) may be reasonable when LDL-C levels are in the range of 160-189 mg/dL or if the lifetime risk is high. Older adults having concomitant risk factors are potential candidates for initiation of statins or continuation of existing statin therapy. In all cases, clinical estimation of risk status is critical in a decision to initiate statins.

For details on the approach to treating hypercholesterolemia in older adults see the Endotext chapter entitled “Management of Dyslipidemia in the Elderly” (65). For details on the approach to treating hypercholesterolemia children and adolescence see the Endotext section on Pediatric Lipidology.


In spite of proven benefit of statin therapy in high-risk patients, there is a relatively high prevalence of nonadherence to the prescribed drug (66). Some studies suggest that up to 50% of patients discontinue use of prescribed statins over the long run (67-70). This finding creates a major challenge to the health care system for prevention of ASCVD. Table 8 lists several factors that may contribute to a high prevalence of nonadherence.

Table 8.

Factors Associated with Statin Nonadherence

Healthcare system factors
Accompanying medical care costs
Lack of medical oversight and follow-up (provider therapeutic inertia)
Provider concern for side effects
Patient factors
Uncertainty of benefit
Lack of health consciousness
Lack of motivation
Lack of perceived benefit
Perceived side effects
Nocebo effects
“Brain fog”
Misattributed symptoms or syndromes (arthritis, spondylosis, neuropathy, insomnia, mental confusion and memory loss, fibromyalgia, gastrointestinal symptoms, liver dysfunction, cataract; cancer).

When a decision is made to initiate statin therapy, the presumption is that statins are a lifetime treatment. Their use is similar to other medications, such as antihypertensive drugs, which are expected to be taken for the rest of one’s life. Such treatments imply indefinite participation in the healthcare system. This means regular ongoing visits to a prescribing clinic. Even for those with medical insurance there are usually co-pays both for the visit and for medication, not to mention cost of transportation to and from the clinic. All of these cost-related issues can be an impediment to long-term statin usage. Provider therapeutic inertia (66) can result from lack of provider education, excessive workload, and concerns about statin side effects.

From the patient’s point of view, common issues are lack of understanding of the potential benefits of therapy and lack of health consciousness and motivation. A related problem is expectation of side effects because of preconditioning by information received from the news media, package inserts, Internet, family, and friends. This expectation can discourage individuals from continuation of statin therapy (nocebo effect) (71). The most common symptoms attributed to statin therapy are muscle pain and tenderness (myalgias) (10). A complaint of statin intolerance is registered in about 5-15% of patients. If myalgias attributed to statins are due to actual pathological changes, the character of the changes is yet to be determined. In almost all cases, serum creatine kinase (CK) levels are not increased. There is no evidence for long-term muscle damage. A few reports nonetheless suggest that statins can produce a low-grade myopathy (72); such an effect has not been widely accepted. The literature is replete with case reports of other symptoms attributed to statins (66). In fact, much of the symptomology reported by patients are unrelated to statin treatment but are in fact the symptoms of other conditions. Statin therapy has been given to large numbers of people for many years without evidence of long-term muscle dysfunction.

Still, in rare cases, especially when blood levels of statins are raised, severe myopathy (rhabdomyolysis) can occur. This proves that statins can be myotoxic. Table 9 lists conditions associated with statin-induced severe myopathy (73,74). In most such cases, severe myopathy is reversible. If the cause can be identified and eliminated, a statin can be cautiously reinstituted. Alternatively, a non-statin LDL-lowering drug (e.g., ezetimibe, bempedoic acid, or PCSK9 inhibitor) can be substituted for the offending statin (10,75).

Table 9.

Factors Associated with Statin - Induced Rhabdomyolysis

Advanced age (>80 y)
Small body frame and fragility
Female sex
Asian ethnicity
Pre-existing neuromuscular condition
Known history of myopathy or family history of myopathy syndrome
Pre-existing liver disease, kidney disease, hypothyroidism
Certain rare genetic polymorphisms
High-dose statin (?)
Postoperative periods
Excessive alcohol intake
Drug interactions (gemfibrozil, antipsychotics, amiodarone, verapamil, cyclosporine, macrolide antibiotics, azole antifungals, protease inhibitors)

These considerations indicate that statin therapy is a much greater investment in time and effort than commonly recognized. Since statins have the potential to prevent many ASCVD events, they offer great potential in clinical management of patients at risk. Nonetheless, to achieve this benefit, the health care system must be adjusted to the requirements of statin therapy as well as other risk-reducing therapies. Unless these adjustments are made, much of the potential benefit of statin treatment will be lost. It will be necessary to address all the components of healthcare and patient factors to improve long-term adherence of statin therapy.


The most influential of European guidelines for management of cholesterol and dyslipidemia are those developed by the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS), and representatives from other European organizations (76). A task force appointed by these organizations have published an update on dyslipidemia management (77). The recommendations of this report resemble in many ways those of the 2018 AHA/ACC guidelines (1). But notable differences can be identified for specific recommendations. A review of these differences may help to identify gaps in knowledge needed to format best recommendations. In the following, recommendations proposed by AHA/ACC and by ESC/EAS will be compared. These comparisons should illuminate areas of uncertainty where more information is needed for definitive recommendations. At the same time, it is important to emphasize that in many critical areas the two sets of guidelines are in strong agreement. These will be noted first.

Agreement Between AHA/ACC and ESC/EAS Guidelines

There is agreement that elevated LDL is the major atherogenic lipoprotein and that LDL-C is the primary target of treatment. Likewise, both guidelines agree that the intensity of LDL-C lowering therapy should depend on absolute risk to patients. In other words, patients who have highest risk should receive the most intensive cholesterol reduction. Both guidelines emphasize therapeutic lifestyle intervention as the foundation of risk reduction, both for elevated cholesterol and for other risk factors. The highest risk patients are those with atherosclerotic disease and are potential candidates for combined drug therapy for cholesterol-lowering. For primary prevention, the intensity of treatment depends on absolute risk as determined by population-based algorithms. For drug therapy, statins are first-line treatment, but in highest risk patients, consideration can be given to adding non-statin drugs (e.g., ezetimibe and PCSK9 inhibitors). Beyond population-based algorithms for primary prevention, measurement of other dyslipidemia markers or other higher risk conditions can be used as risk- enhancing factors to modify intensity of lipid-lowering therapy.

Differences Between AHA/ACC and ESC/EAS Guidelines


This definition is important because it sets the stage for considering combined drug therapy for LDL-C lowering. AHA/ACC defines very high risk as a history of multiple ASCVD events or of one event + multiple high-risk conditions. This limits the definition of very high risk to the highest risk patients among those with ASCVD. In contrast, ESC/EAS considers all patients with clinical ASCVD or ASCVD on imaging as very high risk. Additionally, ESC/EAS allows extension of the definition to highest risk patients in primary prevention, that is, to patients with multiple risk factors and/or subclinical atherosclerosis (table 10). Overall, more patients will be identified as being at very high risk by ESC/EAS guidelines. This could enlarge the usage of PCSK9 inhibitors. AHA/ACC limits the use of PCSK9 inhibitors to patients at highest risk, because of their high cost. One recent study (53) showed that only about 10% of patients with established ASCVD will be eligible for PCSK9 inhibitors by AHA/ACC recommendations.

Table 10.

ESC/EAS Cardiovascular Risk Categories

Very High-Risk
ASCVD, either clinical or unequivocal on imaging
DM with target organ damage or at least three major risk factors or T1DM of long duration (>20 years)
Severe CKD (eGFR <30 mL/min/1.73 m2)
A calculated SCORE >10% for 10-year risk of fatal CVD.
FH with ASCVD or with another major risk factor
Markedly elevated single risk factors, in particular Total Cholesterol >8 mmol/L (>310mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or BP >180/110 mmHg.
Patients with FH without other major risk factors.
Patients with DM without target organ damage, with DM duration > 10 years or another additional risk factor.
Moderate CKD (eGFR 30-59 mL/min/1.73 m2).
A calculated SCORE >5% and <10% for 10-year risk of fatal CVD.
Moderate Risk
Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors.
Calculated SCORE >1% and <5% for 10-year risk of fatal CVD.
Low Risk
Calculated SCORE <1% for 10-year risk of fatal CVD


In 2013, the AHA/ACC eliminated specific numerical goals for LDL-C in both primary and secondary prevention. Recommendations for LDL-C lowering therapy were based exclusively on RCTs of statin therapy. These recommendations have been criticized for lacking a means to evaluate efficacy of statin therapy. In 2018, AHA/ACC identified 2 goals for LDL-C lowering, namely, 50% LDL-C reduction in secondary prevention and 35% reduction in primary prevention. These values are based on the expected reductions achieved by high-intensity statins for secondary prevention and by moderate-intensity statins for primary prevention. Again, no numerical targets are identified. The only exception was the recognition of an LDL-C threshold goal of 1.8 mmol/L (70 mg/dL) for consideration of PCSK9 inhibitors in very high-risk patients on maximal statin therapy + ezetimibe.

ESC/EAS supports the 50% reduction of LDL-C in high-risk patients but also includes a goal of <1.8 mmol/L (70 mg/dL). This goal applies to all high-risk patients, whether in primary or secondary prevention. For very high-risk patients, the goal is an LDL-C of < 1.4 mmol/L (55 mg/dL). For moderate-risk patients in primary prevention, the goal is LDL-C <2.6 mmol/L (100 mg/dL). The guideline task force presumably believed that having defined LDL-C goals facilitates cholesterol-lowering therapy in clinical practice. Additionally, following the ESC/EAS LDL-C goals will most likely result in lower LDL-C levels in many patients.

Table 11.

ESC/EAS LDL Cholesterol Goals

Very High RiskLDL-C reduction of >50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended
High RiskLDL-C reduction of >50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended
Moderate RiskLDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered
Low RiskLDL-C goal <3.0 mmol/L (<116 mg/dL) may be considered.


AHA/ACC employed a pooled cohort equation (PCE) developed from five large population groups in the USA to estimate 10-year risk (and lifetime risk) for ASCVD events. ESC/EAS for several years has employed a SCORE algorithm based on risk for ASCVD mortality in European populations. Both PCE and SCORE are used to define “statin eligibility” for primary prevention. A study suggests that more people are “eligible” for statin therapy using PCE compared to SCORE (78). If this finding can be confirmed, it suggests that ESC/EAS guidelines are less aggressive for reducing LDL-C in lower risk individuals (compared to AHA/ACC guidelines). In contrast, ESC/EAS appears to be more aggressive in use of non-statins for LDL lowering in higher risk patients than is AHA/ACC.


AHA/ACC proposed that several risk enhancing factors favor the decision to use statin therapy in patients at intermediate risk. Although European guidelines did not specify a list of such factors, most were considered to justify more intensive therapy. Notable among risk enhancing factors were apolipoprotein B (apoB) and lipoprotein (a) (Lp[a]). ESC/EAS seemingly placed more emphasis on these two factors for adjusting intensity of therapy; this report’s recommendations can be taken to mean that apoB and Lp(a) should be measured more frequently in risk assessment than stated by AHA/ACC. In fact, neither guideline was highly specific as to when to exercise the option of their measurements. This option depends largely on clinical judgment.


AHA/ACC propose that CAC measurement can assist in deciding whether to use statin therapy in patients at intermediate risk. AHA/ACC in particular noted that the absence of CAC justifies delaying statin therapy. No other modalities of measurement of subclinical atherosclerosis were advocated by AHA/ACC. In contrast, ESC/EAS supported use of different modes of cardiovascular imaging to assist in decisions about intensity of LDL-C lowering therapy. Beyond this, however, recommendations for cardiovascular imaging were not highly specific. Nonetheless, these guidelines suggest that the finding of substantial subclinical atherosclerosis in any arterial bed elevates a patient’s risk to the category of established ASCVD and can justify adding non-statin therapy to statins in such patients.


AHA/ACC guidelines place great emphasis on data from RCTs to justify its recommendations. However, RTC’s related to specific questions typically are limited in number. AHA/ACC recommendations are highly codified and kept to a minimum. ESC/EAS in contrast bases its recommendations both on clinical trials and other types of evidence. It explores available evidence in greater detail, and many of its recommendations are more nuanced. This approach to guideline development has its advantages and disadvantages. For example, it gives the reader a broader base of information to assist in clinical decisions. On the other hand, many of its recommendations are made outside of an RCT-evidence base. Without doubt, cholesterol management in all age and gender groups with various risk factor profiles is complex. The ESC/EAS attempts to provide a rationale for management of this complexity. The AHA/ACC, on the other hand, simplifies management as much as possible; it is written specifically for the practitioner, and leaves the complexities of management to a lipid specialist. ESC/EAS delves into the complexities in more detail so that its recommendations are applicable to both practitioner and specialist.


There are certain key principles that clinicians should remember when deciding who to treat and how aggressively to treat hypercholesterolemia.


The Sooner the Better- atherosclerosis begins early in life and progresses overtime with LDL-C levels playing a major role in the rate of development. Lowering LDL-C levels by lifestyle changes early in life will have long-term benefits. Additionally, in selected individuals initiating drug therapy sooner rather than latter will reduce ASCVD events later in life.


The Lower the Better- studies have clearly demonstrated that the lower the LDL-C levels the greater the decrease in ASCVD events. Clinicians need to balance the benefits of more aggressively lowering LDL-C levels with the risks and costs of high dose or additional drug therapy. It should be recognized that statins and ezetimibe are generic drugs and very inexpensive. In contrast, PCSK9 inhibitors and bempedoic acid are expensive. In many patients using high-intensity statin therapy in combination with ezetimibe can lead to marked reductions in LDL-C levels with minimal risk and at low cost.


The Higher the LDL-C the Greater the Benefit- if the baseline LDL-C is high the magnitude of the reduction in LDL-C will be greater leading to a larger decrease in ASCVD events. Clinicians should be more aggressive in patients with high LDL-C levels.


The Greater the Risk of ASCVD the Greater the Absolute Reduction in ASCVD- clinicians should identify patients at higher risk for ASCVD and more aggressively treat these patients.

Following these general principles will help clinicians make informed decisions in deciding on their approach to lowering LDL-C levels and will facilitate discussions with patients on the benefits and risks of treatment. For an in-depth discussion of these key principles see the following references (79,80).


Advances in the drug therapy of elevated cholesterol levels offer great potential for reducing both new-onset ASCVD and recurrent ASCVD events in those with established disease. This benefit can be enhanced by judicious use of lifestyle intervention. But among drugs, statins are first-line therapy. They are generally safe and inexpensive. They have been shown to reduce ASCVD events in both secondary and primary prevention. Ezetimibe has about half the LDL-lowering efficacy of statins; it too is generally safe, and is a generic relatively inexpensive drug. Ezetimibe can be used as an add-on drug to moderate intensity statins, especially for those who do not tolerate a high-intensity statin. PCSK9 inhibitors are powerful LDL-lowering drugs, and they appear to be largely safe. The major drawback is cost. If the cost of these inhibitors can be reduced, they too have the potential for wide usage, especially in patients who are “statin intolerant”. The major challenge for use of cholesterol-lowering drugs is the problem of long-term non-adherence. Improving adherence will require fundamental changes in the current healthcare system in which patient monitoring and follow-up is often not a high priority.


Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. [PMC free article: PMC7403606] [PubMed: 30586774]
Aragam KG, Natarajan P. Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications. Circ Res. 2020;126:1159–1177. [PMC free article: PMC7926201] [PubMed: 32324503]
Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161:161–172. [PMC free article: PMC4525717] [PubMed: 25815993]
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106:3143-3421. [PubMed: 12485966]
Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367–372. [PMC free article: PMC2539460] [PubMed: 8043072]
Cholesterol Treatment Trialists Collaborators. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. [PMC free article: PMC3437972] [PubMed: 22607822]
Rossouw JE, Lewis B, Rifkind BM. The Value of Lowering Cholesterol after Myocardial Infarction. New England Journal of Medicine. 1990;323:1112–1119. [PubMed: 2215579]
Endo A. The discovery and development of HMG-CoA reductase inhibitors. Journal of Lipid Research. 1992;33:1569–1582. [PubMed: 1464741]
Brown MS, Goldstein JL. A Receptor-Mediated Pathway for Cholesterol Homeostasis. Science. 1986;232:34–47. [PubMed: 3513311]
Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2021.
Cholesterol Treatment Trialists Collaborators. Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. [PubMed: 25579834]
Cholesterol Treatment Trialists’ Collaborators. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. [PMC free article: PMC2988224] [PubMed: 21067804]
Cholesterol Treatment Trialists Collaborators. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393:407–415. [PMC free article: PMC6429627] [PubMed: 30712900]
Cholesterol Treatment Trialists Collaborators. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125. [PubMed: 18191683]
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions. JAMA. 2016;316:1289–1297. [PubMed: 27673306]
The Lipid Research Clinics Coronary Primary Prevention Trial Results. JAMA. 1984;251:351–364. [PubMed: 6361299]
Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS, Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010;95:800–809. [PMC free article: PMC3079219] [PubMed: 19965915]
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. New England Journal of Medicine. 2015;372:2387–2397. [PubMed: 26039521]
Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park J-G, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. Journal of the American College of Cardiology. 2017;69:911–921. [PubMed: 28231942]
Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30:1–9. [PubMed: 30586346]
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine 2014; 371:203-212. [PubMed: 25014686]
Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis. Atherosclerosis. 2011;217:492–498. [PubMed: 21592479]
Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y. Meta-Analysis of Safety of the Coadministration of Statin With Fenofibrate in Patients With Combined Hyperlipidemia. The American Journal of Cardiology. 2012;110:1296–1301. [PubMed: 22840347]
Feingold KR. Triglyceride Lowering Drugs. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2021.
Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Ballantyne CM. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019;380:11–22. [PubMed: 30415628]
Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstrom T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020;324:2268–2280. [PMC free article: PMC7667577] [PubMed: 33190147]
Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of Microsomal Triglyceride Transfer Protein in Familial Hypercholesterolemia. New England Journal of Medicine. 2007;356:148–156. [PubMed: 17215532]
Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M, Apolipoprotein B. Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia. Circulation. 2012;126:2283–2292. [PubMed: 23060426]
Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banerjee P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinreich DM, Yancopoulos GD, Zhang Y, Gaudet D. Elipse HoFH Investigators. Evinacumab for Homozygous Familial Hypercholesterolemia. N Engl J Med. 2020;383:711–720. [PubMed: 32813947]
Adam RC, Mintah IJ, Alexa-Braun CA, Shihanian LM, Lee JS, Banerjee P, Hamon SC, Kim HI, Cohen JC, Hobbs HH, Van Hout C, Gromada J, Murphy AJ, Yancopoulos GD, Sleeman MW, Gusarova V. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J Lipid Res. 2020;61:1271–1286. [PMC free article: PMC7469887] [PubMed: 32646941]
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome. New England Journal of Medicine. 2012;367:2089–2099. [PubMed: 23126252]
HPS3/TIMI55–REVEAL Collaborative Group. Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. New England Journal of Medicine. 2017;377:1217–1227. [PubMed: 28847206]
Lo Surdo P, Bottomley MJ, Calzetta A, Settembre EC, Cirillo A, Pandit S, Ni YG, Hubbard B, Sitlani A, Carfí A. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 2011;12:1300–1305. [PMC free article: PMC3245695] [PubMed: 22081141]
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 2017;376:1713–1722. [PubMed: 28304224]
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine. 2018;379:2097–2107. [PubMed: 30403574]
Cleeman JI, Lenfant C. New guidelines for the treatment of high blood cholesterol in adults from the National Cholesterol Education Program. From controversy to consensus. Circulation. 1987;76:960–962. [PubMed: 3308167]
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Archives of Internal Medicine. 1988;148:36–69. [PubMed: 3422148]
National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 1994;89:1333–1445. [PubMed: 8124825]
Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Stone NJ. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology. 2004;44:720–732. [PubMed: 15358046]
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC, Watson K, Wilson PWF. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology. 2014;63:2889–2934. [PubMed: 24239923]
Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice G. In: Graham R MM, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011. [PubMed: 24983061]
Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB Sr, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014;63:2935–2959. [PMC free article: PMC4700825] [PubMed: 24239921]
Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd-Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations. JAMA. 2014;311:1406–1415. [PMC free article: PMC4189930] [PubMed: 24682252]
Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. The Lancet. 2013;382:1762–1765. [PubMed: 24268611]
Kavousi M, Leening MJG, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of Application of the ACC/AHA Guidelines, Adult Treatment Panel III Guidelines, and European Society of Cardiology Guidelines for Cardiovascular Disease Prevention in a European Cohort. JAMA. 2014;311:1416–1423. [PubMed: 24681960]
DeFilippis AP, Young R, Carrubba CJ, McEvoy JW, Budoff MJ, Blumenthal RS, Kronmal RA, McClelland RL, Nasir K, Blaha MJ. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. Ann Intern Med. 2015;162:266–275. [PMC free article: PMC4414494] [PubMed: 25686167]
Damen JA, Pajouheshnia R, Heus P, Moons KGM, Reitsma JB, Scholten RJPM, Hooft L, Debray TPA. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis. BMC Med. 2019;17:109–109. [PMC free article: PMC6563379] [PubMed: 31189462]
Rana JS, Tabada GH, Solomon MD, Lo JC, Jaffe MG, Sung SH, Ballantyne CM, Go AS. Accuracy of the Atherosclerotic Cardiovascular Risk Equation in a Large Contemporary, Multiethnic Population. Journal of the American College of Cardiology. 2016;67:2118–2130. [PMC free article: PMC5097466] [PubMed: 27151343]
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine. 2008;359:2195–2207. [PubMed: 18997196]
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–e646. [PMC free article: PMC7734661] [PubMed: 30879355]
Feingold KR. The Effect of Diet on Cardiovascular Disease and Lipid and Lipoprotein Levels. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2021.
Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017;2:1069–1078. [PMC free article: PMC5710446] [PubMed: 28832867]
Virani SS, Akeroyd JM, Smith SC, Al-Mallah M, Maddox TM, Morris PB, Petersen LA, Ballantyne CM, Grundy SM, Stone NJ. Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. Journal of the American College of Cardiology. 2019;74:712–714. [PubMed: 31370962]
Khera AV, Won H-H, Peloso GM, Lawson KS, Bartz TM, Deng X, van Leeuwen EM, Natarajan P, Emdin CA, Bick AG, Morrison AC, Brody JA, Gupta N, Nomura A, Kessler T, Duga S, Bis JC, van Duijn CM, Cupples LA, Psaty B, Rader DJ, Danesh J, Schunkert H, McPherson R, Farrall M, Watkins H, Lander E, Wilson JG, Correa A, Boerwinkle E, Merlini PA, Ardissino D, Saleheen D, Gabriel S, Kathiresan S. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology. 2016;67:2578–2589. [PMC free article: PMC5405769] [PubMed: 27050191]
Warden BA, Fazio S, Shapiro MD. Familial Hypercholesterolemia: Genes and Beyond. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2000.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344:1383–1389. [PubMed: 7968073]
Kashef MA, Giugliano G. Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS). Glob Cardiol Sci Pract. 2016;2016:e201635–e201635. [PMC free article: PMC5624184] [PubMed: 28979904]
Feingold KR. Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2020.
Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, Blumenthal RS. Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019;139:e1162–1177. [PubMed: 30586766]
Horton JD, Cohen JC, Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res. 2009;50 Suppl:S172–177. [PMC free article: PMC2674748] [PubMed: 19020338]
Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Kastelein JJP, Nicholls SJ. Mendelian Randomization Study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380:1033–1042. [PMC free article: PMC7612927] [PubMed: 30865797]
Yebyo HG, Aschmann HE, Kaufmann M, Puhan MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American Heart Journal. 2019;210:18–28. [PubMed: 30716508]
Tota-Maharaj R, Blaha MJ, Blankstein R, Silverman MG, Eng J, Shaw LJ, Blumenthal RS, Budoff MJ, Nasir K. Association of coronary artery calcium and coronary heart disease events in young and elderly participants in the multi-ethnic study of atherosclerosis: a secondary analysis of a prospective, population-based cohort. Mayo Clin Proc. 2014;89:1350–1359. [PMC free article: PMC4424047] [PubMed: 25236430]
Stone NJ, Smith SC Jr, Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M, Pencina MJ, Grundy SM. Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:819–836. [PubMed: 35210038]
Streja E, Streja DA. Management of Dyslipidemia in the Elderly. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, eds. Endotext. South Dartmouth (MA)2000.
Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. International Journal of Cardiology. 2016;225:184–196. [PubMed: 27728862]
Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, LeLorier J. Persistence of Use of Lipid-Lowering Medications. JAMA. 1998;279:1458. [PubMed: 9600480]
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid‐lowering drugs. Medical Journal of Australia. 1996;164:208–211. [PubMed: 8604188]
Gamboa CM, Safford MM, Levitan EB, Mann DM, Yun H, Glasser SP, Woolley JM, Rosenson R, Farkouh M, Muntner P. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348:108–114. [PMC free article: PMC4108514] [PubMed: 24892511]
Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol. 2005;21:485–488. [PubMed: 15917876]
Tobert JA, Newman CB. The nocebo effect in the context of statin intolerance. Journal of Clinical Lipidology. 2016;10:739–747. [PubMed: 27578103]
Golomb BA, Evans MA. Statin Adverse Effects: a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs. 2008;8:373–418. [PMC free article: PMC2849981] [PubMed: 19159124]
Fitchett DH, Hegele RA, Verma S. Statin Intolerance. Circulation. 2015;131:e389–391. [PubMed: 25825402]
Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. American College of C, American Heart A, National Heart L, Blood I. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation. 2002;106:1024–1028. [PubMed: 12186811]
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. JAMA. 2016;315:1580–1590. [PubMed: 27039291]
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen M-R, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal. 2016;37:2999–3058. [PubMed: 27567407]
Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, Group ESCSD. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. [PubMed: 31504418]
Lee JC, Zdrojewski T, Pencina MJ, Wyszomirski A, Lachacz M, Opolski G, Bandosz P, Rutkowski M, Gaciong Z, Wyrzykowski B, Navar AM. Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. JAMA Cardiol. 2016;1:700–707. [PMC free article: PMC5803077] [PubMed: 27434662]
Feingold KR, Chait A. Approach to patients with elevated low-density lipoprotein cholesterol levels. Best Pract Res Clin Endocrinol Metab. 2022:101658. [PubMed: 35487874]
Feingold KR. Maximizing the benefits of cholesterol-lowering drugs. Curr Opin Lipidol. 2019;30:388–394. [PubMed: 31335331]
Copyright © 2000-2023, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

Bookshelf ID: NBK305897PMID: 26247090


  • PubReader
  • Print View
  • Cite this Page


Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...